Application:
- Psychiatric disorders, such as schizophrenia and major depression, are complex chronic conditions characterized by repeated hospitalizations, some of which are prolonged, numerous clinic visits, and various treatment attempts. Current psychiatric drug treatments offer only partial relief of symptoms for some patients and are known for their long reaction times and numerous side effects. Patients often experience multiple symptoms simultaneously, necessitating combined treatments. Currently, there is no specific medication indicated to treat different symptoms simultaneously.
- Labels for psychiatric medications are based solely on double-blind studies and describe specific disorders in general terms. Treatment is not personalized, and predicting a patient’s response to a particular treatment is challenging. Patients with psychiatric disorders often suffer from underlying illnesses and take multiple medications, leading to polypharmacy.
Our innovation:
Our innovation consists of:
1. A software system for clinical decision support for the pharma companies (algorithms and UI),
2. Automated generation of hypotheses/insights toward future development of novel combination therapies.
Our goal is to predict which drug combinations are beneficial for specific populations of patients.
Advantages:
- Use of artificial intelligence to identify and predict the beneficial effects of drug combinations, including doses, for the personalized treatment of psychiatric disorders. –
- Collection of information on treatments and indicators of medical conditions from medical records, which include both Hebrew text and tabular data. The goal is to predict which combinations are beneficial for specific populations of patients and diagnoses.
Opportunity:
Our technology will serve as the foundation for a clinical decision support system and will help pharmaceutical companies identify opportunities to develop new combination therapies.
We are seeking collaboration with companies searching for new technologies and products for AI-based healthcare products.
Contact in Yissum: Anna Pellivert
